Concepción R, García-Jiménez Y, Ávalos-Oddi A

Idioma: Inglés [English version]
Referencias bibliográficas: 15
Paginas: s450-453
Archivo PDF: 174.16 Kb.

REFERENCIAS (EN ESTE ARTÍCULO)

1. American Psychiatric Association et al. Diagnostic and statistical manual of mental disorders, text revision (DSM-IV-TR®). 2010.

2. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015; 72: 334-341.

3. Santomauro DF, Mantilla A, Shadid J, Zheng P, Ashbaugh C, Pigott DM et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. LANCET. 2021; 398: 1700-1712.

4. AbuRuz ME, Al-Dweik G. Depressive symptoms and complications early after acute myocardial infarction: gender differences. Open Nurs J. 2018; 12: 205-214.

5. O'Neil A, Russell JD, Murphy B. How does mental health impact women's heart health? Heart Lung Circ. 2021; 30: 59-68.

6. Lopez Rossetti Daniel. Ellas, Cerebro, corazón y psicología de la mujer. 2016 Editorial Planeta.

7. Levine GN, Cohen BE, Commodore-Mensah Y, Fleury J, Huffman JC, Khalid U, et al. Psychological health, well-being, and the mind-heart-body connection: a Scientific Statement From the American Heart Association. Circulation. 2021; 143: e763-e783.

8. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Krubzansky L. The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology. J Am Coll Cardiol. 2005; 45: 637-651.

9. Osborne MT, Shin LM. Disentangling the links between psychosocial stress and cardiovascular disease. Circ Cardiovasc Imaging. 2020; 13: e010931.

10. Manish KJ, Qamar A, Vaduganathan M, Charney DS, Murrough JW. Screening and management of depression in patients with cardiovascular disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 73: 1827-1845.

11. OMS. Guía de intervención mhGAP para los trastornos mentales, neurológicos y por consumo de sustancias en el nivel de atención de salud no especializada. Versión 2.0. [Visitado el 8 de agosto de 2022] Disponible en: https://iris.paho.org/handle/10665.2/3407

12. Piña IL, Di Palo KE, Ventura HO. Psychopharmacology and cardiovascular disease. J Am Coll Cardiol. 2018; 71: 2346-2359.

13. MacQueen GM, Frey BN, Ismail Z, Jaworska N, Steiner M, Lieshout RJ et al. Canadian Network for Mood and Anxiety Treatments (CANMAT). 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly [published correction appears in Can J Psychiatry. 2017; 62: 356. Can J Psychiatry.2016; 61: 588-603.

14. Scott-Sheldon LAJ, Gathright EM, Donahue ML, Balletto B, Feulner MM, DeCosta J et al. Mindfulness-based interventions for adults with cardiovascular disease: A systematic review and meta-analysis. Ann Behav Med. 2020; 54: 67-73.

15. Bourbeau K, Moriarty T, Ayanniyi A, Zuhl M. The combined effect of exercise and behavioral therapy for depression and anxiety: systematic review and meta-analysis. Behav Sci. 2020; 10: 116.